Antibody effector mechanisms in myasthenia gravis - The complement hypothesis

Annals of the New York Academy of Sciences

Volumn 841, Issue , 1998, Pages 450-465

  Richman, David P ^a   Agius, Mark A ^a   Kirvan, Christine A ^a,c   Gomez, Christopher M ^b   Fairclough, Robert H ^a   Dupont, Bonita L ^a,c   Maselli, Ricardo A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Myasthenia Foundation of America   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD4 ANTIGEN; COMPLEMENT; COMPLEMENT COMPONENT C1Q; FC RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; NICOTINIC RECEPTOR;

ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; COMPLEMENT ACTIVATION; CONFERENCE PAPER; HUMAN; IMMUNOPATHOGENESIS; MACROPHAGE; MYASTHENIA GRAVIS; NERVE ENDING; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROTEIN CROSS LINKING; RECEPTOR DENSITY; T LYMPHOCYTE;

EID: 0031879898     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1998.tb10962.x     Document Type: Article

References (67)

1. PATRICK, J. & J. LINDSTROM. 1973. Autoimmune response to acetylcholine receptor. Science 180: 871-872.
2. DRACHMAN, D. B. 1994. Myasthenia gravis. N. Engl. J. Med. 330: 1797-1810.
3. RICHMAN, D. P. & M. A. AGIUS. 1994. Acquired myasthenia gravis: immunopathology. Neurol. Clin. North Am. 12: 273-284.
4. LENNON, V. A., J. M. LINDSTROM & M. E. SEYBOLD. 1975. Experimental autoimmune myasthenia gravis (EAMG): a model of myasthenia gravis in rats and guinea pigs. J. Exp. Med. 141: 1365-1375.
5. ABRAMSKY, O., A. AHARONOV, D. TEITELBAUM et al. 1975. Myasthenia gravis and acetylcholine receptor: effect of steroids in clinical course and cellular immune response to acetylcholine receptor. Arch. Neurol. 32: 684-687.
6. RICHMAN, D. P., J. PATRICK & B. G. W. ARNASON. 1976. Cellular immunity in myasthenia gravis: response to purified acetylcholine receptor and autologous thymocytes. N. Engl. J. Med. 294: 694-698.
7. HOHLFELD, R., I. KALIES, B. KOHLEISEN, K. HEININGER, B. CONTI-TRONCONI & K. TOYKA. 1986. Myasthenia gravis: stimulation of antireceptor autoantibodies by autoreactive T cell lines. Neurology 36: 618-621.
8. PROTTI, M. P., A. A. MANFREDI, C. STRAUB, J. F. J. HOWARD & B. M. CONTI-TRONCONI. 1990. CD4+ T cell response to the human acetylcholine receptor alpha subunit in myasthenia gravis: a study with synthetic peptides. J. Immunol. 144: 1276-1281.
9. NAKAKO, S. & A. G. ENGEL. 1993. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of membrane attack complex at the endplate in 30 patients. Neurology 43: 1167-1172.
10. CONTI-TRONCONI, B. M. et al. 1994. The nicotinic acetylcholine receptor: structure and autoimmune pathology. Crit. Rev. Biochem. Mol. Biol. 29: 69-123.
11. + T cells are essential to induce experimental autoimmune myasthenia gravis. J. Exp. Med. 184: 349.
12. + antibody: improvement correlates to decreased T-cell autoreactivity. Neurology 44: 1732-1737.
13. KARLIN, A. & M. AKABAS. 1995. Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins. Neuron 15: 1231-1244.
14. TZARTOS, S., M. SEYBOLD & J. LINDSTROM. 1982. Specificity of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 79: 188-192.
15. TZARTOS, S., M. CUNG, P. DEMANGE, H. LOUTRARI, A. MAMALAKI, M. MARRAUD, I. PAPADOUII, C. SAKARELLOS & V. TSIKARIS. 1991. The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies. Mol. Neurobiol. 5: 1-29.
16. LENNON, V. A. & G. E. GRIESMANN. 1989. Evidence against acetylcholine receptor having a main immunogenic region as target for autoantibodies in myasthenia gravis. Neurology 39: 1069-1076.
17. YOKOI, T., B. MULAC-JERICEVIC, J. KURISAKI & M. Z. ATASSI. 1987. T lymphocyte recognition of acetylcholine receptor: localization of the full T cell recognition profile on the extracellular part of the a chain of Torpedo californica acetylcholine receptor. Eur. J. Immunol. 17: 1697.
18. BELLONE, M., N. OSTLIE, S. LEI & B. M. CONTI-TRONCONI. 1991. Experimental myasthenia gravis in congenic mice: sequence mapping and H-2 restriction of T helper epitopes on the a subunits of Torpedo californica and murine acetylcholine receptors. Eur. J. Immunol. 21: 2303.
19. SHENOY, M., E. GOLUSZKO & P. CHRISTADOSS. 1994. The pathogenic role of acetylcholine receptor alpha chain epitope within alpha 146-162 in the development of experimental autoimmune myasthenia gravis in C57BL6 mice. Clin. Immunol. Immunopathol. 73: 338-343.
20. PROTTI, M. P. et al. 1993. Myasthenia gravis: recognition of a human autoantigen at the molecular level. Immunol. Today 14: 363-368.
21. DORRINGTON, K. J. 1985. The functional differentiation of the Fc region of immunoglobulin G. Ann. Inst. Pasteur Immunol. 136C: 260-263.
22. DUNCAN, A. R. & G. WINTER. 1988. The binding site for Clq on IgG. Nature 332: 738-740.
23. H2 domain and is modulated by the hinge region. J. Exp. Med. 173: 1483-1491.
24. H2 domain of IgG for mouse FCγRII. Mol. Immunol. 29: 53-59.
25. XU, Y., R. OOMEN & M. H. KLEIN. 1994. Residue at position 331 in the IgG1 and IgG4 CH2 domains contributes to their differential ability to bind and activate complement. J. Biol. Chem. 269: 3469-3474.
26. MORGAN, A., N. D. JONES, A. M. NESBITT, L. CHAPLIN, M. W. BOOMER & J. S. EMTAGE. 1995. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for Clq, Fc gamma RI, and Fc gamma RIII binding. Immunology 86: 319-324.
27. WARD, E. S. & V, GHETIE. 1995. The effector functions of immunoglobulins: implications for therapy. Ther. Immunol. 2: 77-94.
28. MILETIC, V. D. & M. M. FRANK. 1995. Complement-immunoglobulin interactions. Curr. Opin. Immunol. 7: 41-47.
29. LUND, J., G. WINTER, P. T. JONES, J. D. POUND, T. TANAKA, M. R. WALKER, P. J. ARTYMIUK, Y. ARATA, D. R. BURTON, R. JEFFERIS & J. J. WOOF. 1991. Human FcγRI and FcγRII interact with distinct but overlapping sites on human IgG1. J. Immunol. 147: 2657-2662.
30. MICHAELSEN, T. E., A. AASE, L. NORDERHAUG & I. SANDLIE. 1992. Antibody dependent cell-mediated cytotoxicity induced by chimeric mouse-human IgG subclasses and IgG3 antibodies with altered hinge region. Mol. Immunol. 29: 319-326.
31. VAN GOOR, H., G. DING, D. KEES-FOLTS, J. GROND, G. F. SCHREINER & J. R. DIAMOND. 1994. Macrophages and renal disease. Lab. Invest. 71: 456-464.
32. LINDSTROM, J., D. SHELTON & Y. FUJII. 1988. Myasthenia gravis. Adv. Immunol. 12: 233-284.
33. ENGEL, A. G. & G. FUMAGALLI. 1982. Mechanisms of acetylcholine receptor loss from the neuromuscular junction. Ciba Found. Symp. 90: 197-224.
34. ENGEL, A. G. 1980. Morphological and immunopathological findings in myasthenia gravis and congenital myasthenic syndromes. J. Neurol. Neurosurg. Psychiatry 43: 577.
35. LINDSTROM, J. M., A. G. ENGEL, M. E. SEYBOLD, V. A. LENNON & E. LAMBERT. 1976. Pathological mechanisms in experimental autoimmune myasthenia in rats with anti-acetylcholine receptor antibodies. J. Exp. Med. 144: 739.
36. BEVAN, S., R. W. KUHLBERG & S. F. HEINEMANN. 1977. Human myasthenia sera reduce acetylcholine sensitivity of human muscle cells in tissue culture. Nature 276: 262.
37. GOMEZ, C. M. & D. P. RICHMAN. 1983. Anti-acetylcholine receptor antibodies directed against the α-bungarotoxin binding site induce a unique form of experimental myasthenia. Proc. Natl. Acad. Sci. U.S.A. 80: 4089-4093.
38. DRACHMAN, D. B., R. N. ADAMS, L. F. JOSIFEK & S. G. SELF. 1982. Functional activities of auto-antibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N. Engl. J. Med. 307: 769.
39. PACHNER, A. R. 1989. Anti-acetylcholine receptor antibodies block bungarotoxin binding to native human acetylcholine receptor on the surface of TE671 cells. Neurology 39: 1057-1061.
40. MIHOVILOVIC, M., D. DONNELLY-ROBERTS, D. P. RICHMAN & M. MARTINEZ-CARRION. 1994. Pathogenesis of hyperacute experimental autoimmune myasthenia gravis. J. Immunol. 152: 5997-6002.
41. KAO, I. & D. DRACHMAN. 1977. Myasthenie immunoglobulin accelerates acetylcholine receptor degradation. Science 196: 526.
42. LENNON, V. A. et al. 1975. Experimental autoimmune myasthenia gravis (EAMG): a model of myasthenia gravis in rats and guinea pigs. J. Exp. Med. 141: 1365.
43. SOHASHI, K., A. ENGEL, J. LINDSTROM & E. LAMBERT. 1978. Ultrastructural localization of immune complexes at the endplate in experimental autoimmune myasthenia gravis. J. Neuropathol. 37:212.
44. GOMEZ, C. M., D. P. RICHMAN, P. W. BERMAN et al. 1979. Monoclonal antibodies against purified nicotinic acetylcholine receptor. Biochem. Biophys. Res. Commun. 88: 575-582.
45. LENNON, V. A. & E. H. LAMBERT. 1980. Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptors. Nature 285: 238.
46. MOSHLY-ROSEN, D., S. FUCHS & Z. ESBHAR. 1979. Monoclonal antibodies against defined determinants of acetylcholine receptor. FEBS Lett. 106: 389.
47. RICHMAN, D. P., C. M. GOMEZ, P. W. BERMAN et al. 1980. Monoclonal anti-acetylcholine receptor antibodies can cause experimental myasthenia. Nature 286: 738.
48. GOMEZ, C. M., R. L. WOLLMANN & D. P. RICHMAN. 1984. Induction of the morphologic changes of both acute and chronic experimental myasthenia by monoclonal antibody directed against acetylcholine receptor. Acta Neuropathol. 63: 131-143.
49. LENNON, V., M. SEYBOLD, J. LINDSTROM et al. 1978. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J. Exp. Med. 147: 973-983.
50. CHRISTADOSS, P. 1988. C5 gene influences the development of murine myasthenia gravis. J. Immunol. 140: 2589-2592.
51. BIESECKER, G. & C. M. GOMEZ. 1989. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J. Immunol. 142: 2654-2659.
52. DUPONT, B. L. & D. P. RICHMAN. 1987. Complement activation by anti-acetylcholine receptor monoclonal antibody in vitro correlates with potency of EAMG response in vivo. Ann. N.Y. Acad. Sci. 505: 725-727.
53. MASELLI, R. A., D. P. RICHMAN & R. L. WOLLMANN. 1991. Inflammation at the neuromuscular junction in myasthenia gravis. Neurology 41: 1497-1504.
54. LOUTRARI, H., A. KOKLA & S. J. TZARTOS. 1992. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor. Eur. J. Immunol. 22: 2449-2452.
55. TZARTOS, S. J. & J. M. LINDSTROM. 1980. Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits. Proc. Natl. Acad. Sci. U.S.A. 77: 755.
56. LENNON, V. A. & E. H. LAMBERT. 1980. Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptors. Nature 285: 238.
57. BUZZARD, E. F. 1905. The clinical history and post-mortem examination of five cases of myasthenia gravis. Brain 28: 438.
58. LISAK, R. P. & R. L. BARCHI. 1982. In Myasthenia Gravis, p. 97-98. Saunders. Philadelphia.
59. RUSSELL, D. S. 1953. Histological changes in the stripped muscles in myasthenia gravis. J. Pathol. Bacteriol. 65: 279-289.
60. PASCUZZI, R. M. & J. F. CAMPA. 1988. Lymphorrhage localized to the muscle end-plate in myasthenia gravis. Arch. Pathol. Lab. Med. 112: 934-937.
61. COREY, A. L., D. P. RICHMAN, C. A. SCHUMAN, C. M. GOMEZ & B. G. W. ARNASON. 1985. Use of monoclonal antiacetylcholine receptor antibodies to investigate the macrophage inflammation of acute experimental myasthenia gravis: refractoriness to a second episode of acute disease. Neurology 35: 1455-1460.
62. COREY, A. L., D. P. RICHMAN, R. L. WOLLMANN & M. A. AGIUS. 1987. Refractoriness to a second episode of experimental myasthenia gravis: correlation with acetylcholine receptor concentration and morphologic appearance of the post-synaptic membrane. J. Immunol. 138: 3269-3275.
63. RICHMAN, D. P., R. L. WOLLMANN, R. A. MASELLI, C. M. GOMEZ, A. L. COREY, M. A. AGIUS & R. H. FAIRCLOUGH. 1993. Effector mechanisms of myasthenic antibodies. Ann. N.Y. Acad. Sci. 681: 264-273.
64. GOMEZ, C. M., D. P. RICHMAN, S. A. BURRES & B. G. W. ARNASON. 1981. Monoclonal hybridoma anti-acetylcholine receptor antibodies: antibody specificity and effect of passive transfer. Ann. N.Y. Acad. Sci. 377: 97-109.
65. DUPONT, B. L., G. M. TWADDLE & D. P. RICHMAN. 1987. Suppression of passive transfer acute experimental myasthenia by F(ab′)2 fragments. J. Neuroimmunol. 16: 47.
66. KIRVAN, C. A., S. ZHU, D. P. RICHMAN & M. A. AGIUS. 1998. Expression and initial characterization of recombinant antiacetylcholine receptor antibodies in experimental autoimmune myasthenia gravis. This volume.
67. AGIUS, M. A., B. SANYAL & D. P. RICHMAN. 1993. Molecular structure of a monoclonal antiacetylcholine receptor antibody and of a corresponding monoclonal antiidiotopic antibody. Ann. N.Y. Acad. Sci. 681: 274-275.